Home / Congenital and Juvenile-Onset Clinical Trial Launches

Congenital and Juvenile-Onset Clinical Trial Launches

AMO Pharma Limited (AMO Pharma) announced initiation of a phase 2 clinical study in the U.K. for AMO-02 (tideglusib) on August 10, 2016. This phase 2 exploratory study focuses on adult and adolescent patients with congenital and juvenile onset myotonic dystrophy. This is the first sponsor-led clinical study evaluating an investigational therapy in this patient group as part of a development program. 

For AMO Pharma's announcement on the clinical trial, click here. Click here for more detail on the trial at clinicaltrials.gov. For more information on AMO Pharma, click here.

Partners

University of Florida Logo 100px.png Houston Methodist Logo 100px.png University of Iowa 100px.png University of Kansas Logo 100px.png National Institute of Health 100px.png Ohio State University Logo 100px.png University of Rochester 100px.png Stanford University Logo 100px.png University of Utah Logo 100px.png Virginia Commonwealth University Logo 100px.png Wyck Logo 150px.png

© Myotonic Dystrophy Foundation. All rights reserved.